Ad3-hTERT-E1A
AXP000072.1 · Oncolytic virus
- Platform
- adenovirus (serotype 3, hTERT promoter-driven E1A)
- Originator
- University of Helsinki (Akseli Hemminki)
Names
| Name | Type | Source |
|---|---|---|
| Ad3-hTERT-E1A | preferred name, code | curator, paper |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 3 (NCBI Taxonomy 45659)
- Strain
- Ad3
- Replication
- conditionally replicating
- Modifications
- hTERT promoter drives E1A
- Route
- intratumoral, intraperitoneal, intrapleural, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (0)
No trial in the latest ClinicalTrials.gov snapshot names this program.
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 22871667 | Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in title: Ad3-hTERT-E1A |
| PMID 21183947 | Oncolytic adenovirus based on serotype 3. | Cancer gene therapy | 2011 | name in abstract: Ad3-hTERT-E1A |
Notes
ATAP construct (2007-2012); a rare fully serotype-3 oncolytic adenovirus.
How to cite
Ad3-hTERT-E1A (AXP000072.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000072.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.